DE60030274D1 - Aus ganzen zellen bestehender impfstoff, der staphylococcus aureus antigen enthält - Google Patents

Aus ganzen zellen bestehender impfstoff, der staphylococcus aureus antigen enthält

Info

Publication number
DE60030274D1
DE60030274D1 DE60030274T DE60030274T DE60030274D1 DE 60030274 D1 DE60030274 D1 DE 60030274D1 DE 60030274 T DE60030274 T DE 60030274T DE 60030274 T DE60030274 T DE 60030274T DE 60030274 D1 DE60030274 D1 DE 60030274D1
Authority
DE
Germany
Prior art keywords
antigen
aureus
vaccine
type
staphylococcus aureus
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60030274T
Other languages
English (en)
Other versions
DE60030274T2 (de
Inventor
I Fattom
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nabi Biopharmaceuticals Inc
Original Assignee
Nabi Biopharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nabi Biopharmaceuticals Inc filed Critical Nabi Biopharmaceuticals Inc
Application granted granted Critical
Publication of DE60030274D1 publication Critical patent/DE60030274D1/de
Publication of DE60030274T2 publication Critical patent/DE60030274T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/521—Bacterial cells; Fungal cells; Protozoal cells inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Mycology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pathology (AREA)
  • Genetics & Genomics (AREA)
  • Virology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Transplantation (AREA)
  • Diabetes (AREA)
DE60030274T 1999-05-10 2000-05-10 Aus ganzen zellen bestehender impfstoff, der staphylococcus aureus antigen enthält Expired - Lifetime DE60030274T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US307775 1989-02-07
US09/307,775 US6294177B1 (en) 1996-09-11 1999-05-10 Staphylococcus aureus antigen-containing whole cell vaccine
PCT/US2000/012589 WO2000067785A2 (en) 1999-05-10 2000-05-10 Staphyloccocus aureus antigen-containing whole cell vaccine

Publications (2)

Publication Number Publication Date
DE60030274D1 true DE60030274D1 (de) 2006-10-05
DE60030274T2 DE60030274T2 (de) 2008-01-10

Family

ID=23191126

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60030274T Expired - Lifetime DE60030274T2 (de) 1999-05-10 2000-05-10 Aus ganzen zellen bestehender impfstoff, der staphylococcus aureus antigen enthält

Country Status (15)

Country Link
US (2) US6294177B1 (de)
EP (1) EP1178824B1 (de)
JP (1) JP2002544169A (de)
AT (1) ATE337015T1 (de)
AU (1) AU777218B2 (de)
BR (1) BR0010478A (de)
CA (1) CA2372633C (de)
CY (1) CY1105744T1 (de)
DE (1) DE60030274T2 (de)
DK (1) DK1178824T3 (de)
ES (1) ES2270835T3 (de)
MX (1) MXPA01011507A (de)
NZ (1) NZ515394A (de)
PT (1) PT1178824E (de)
WO (1) WO2000067785A2 (de)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6610293B1 (en) * 1997-06-16 2003-08-26 The Henry M. Jackson Foundation For The Advancement Of Military Medicine Opsonic and protective monoclonal and chimeric antibodies specific for lipoteichoic acid of gram positive bacteria
US6936258B1 (en) * 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine
US6974573B2 (en) * 1999-11-01 2005-12-13 Mucovax Holdings, B.V. Antibody production in farm animals
US20030096315A1 (en) 2000-05-03 2003-05-22 Sanders Mitchell C. Device for detecting bacterial contamination and method of use
EP2320233A1 (de) * 2001-06-15 2011-05-11 Inhibitex, Inc. Kreuzreaktive monoklonale und polyklonale Antikörper, die Oberflächenprotein aus Koagulasenegativen Staphylococci und Staphylococcus aureus erkennen
US9017963B2 (en) * 2002-01-31 2015-04-28 Woundchek Laboratories (Us), Inc. Method for detecting microorganisms
EP1487273B1 (de) 2002-02-13 2009-01-21 Immunology Laboratories, Inc. Zusammensetzungen und verfahren für die behandlung von mikroorganismen-infektionen
US6984381B2 (en) 2002-07-05 2006-01-10 The United States Of America As Represented By The Secretary Of Agriculture Vaccine for the prevention of bacterial infection of the bovine mammary gland
ES2648046T3 (es) * 2002-11-12 2017-12-28 The Brigham And Women's Hospital, Inc. Vacuna de polisacárido para infecciones estafilocócicas
EP2305294B1 (de) 2004-09-22 2015-04-01 GlaxoSmithKline Biologicals SA Immunogene Zusammensetzung zur Verwendung zur Impfung gegen Staphylokokken
US20060153857A1 (en) * 2005-01-10 2006-07-13 Nabi Biopharmaceuticals Method of treating staphylococcus aureus infection
US20060228368A1 (en) * 2005-04-07 2006-10-12 Nabi Biopharmaceuticals Method of protecting against staphylococcal infection
CN102698261A (zh) 2005-06-13 2012-10-03 葛兰素史密斯克蓝生物品公司 Panton-valentine杀白细胞素用于治疗和预防葡萄球菌感染的用途
KR101541383B1 (ko) * 2006-03-30 2015-08-03 글락소스미스클라인 바이오로지칼즈 에스.에이. 면역원성 조성물
CN101466406B (zh) 2006-06-12 2012-06-27 葛兰素史密斯克蓝生物品公司 α-毒素在治疗和预防葡萄球菌感染上的用途
WO2008085549A2 (en) * 2006-07-28 2008-07-17 Board Of Regents Of The University Of Texas System Compositions and methods for stimulation of lung innate immunity
US8465754B2 (en) 2007-05-28 2013-06-18 Kitasato Daiichi Sankyo Vaccine Co., Ltd. Bordetella parapertussis whole-cell vaccine composition
WO2009013443A1 (en) * 2007-07-23 2009-01-29 Vaccine Research International Plc Inactivated staphylococcal whole-cell vaccine
WO2009029831A1 (en) * 2007-08-31 2009-03-05 University Of Chicago Methods and compositions related to immunizing against staphylococcal lung diseases and conditions
US9181329B2 (en) 2007-08-31 2015-11-10 The University Of Chicago Methods and compositions related to immunizing against Staphylococcal lung diseases and conditions
CN105085349B (zh) * 2008-07-21 2018-02-09 布赖汉姆妇女医院 与合成的β‑1,6 葡糖胺寡糖相关的方法和组合物
WO2010014304A1 (en) * 2008-07-29 2010-02-04 University Of Chicago Compositions and methods related to staphylococcal bacterium proteins
WO2010030790A2 (en) * 2008-09-10 2010-03-18 The Texas A&M University System Methods and compositions for stimulation of mammalian innate immune resistance to pathogens
AU2009302582A1 (en) 2008-10-06 2010-04-15 University Of Chicago Compositions and methods related to bacterial Eap, Emp, and/or AdsA proteins
US20100150942A1 (en) * 2008-12-03 2010-06-17 Cantor Thomas L Affinity purified human polyclonal antibodies and methods of making and using them
EP2411521B1 (de) 2009-03-25 2015-01-14 The Board of Regents of The University of Texas System Zusammensetzungen zur stimulierung angeborener säuger-immunresistenz gegen krankheitserreger
KR101773368B1 (ko) 2009-04-03 2017-08-31 유니버시티 오브 시카고 단백질 Ａ(ＳｐＡ) 변이체와 관련된 조성물 및 방법
GB0913680D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
GB0913681D0 (en) 2009-08-05 2009-09-16 Glaxosmithkline Biolog Sa Immunogenic composition
PT2493498T (pt) * 2009-10-30 2017-05-24 Glaxosmithkline Biologicals Sa Purificação de sacáridos capsulares de staphylococcus aureus tipo 5 e tipo 8
JP2013523818A (ja) 2010-04-05 2013-06-17 ザ・ユニバーシティー・オブ・シカゴ 免疫反応のエンハンサーとしてのプロテインＡ（ＳｐＡ）抗体に関連する組成物および方法
CN103037885B (zh) 2010-07-02 2015-08-26 芝加哥大学 与蛋白A(SpA)变体相关的组合物和方法
JP5793194B2 (ja) 2010-09-09 2015-10-14 ザ・ユニバーシティ・オブ・シカゴＴｈｅ Ｕｎｉｖｅｒｓｉｔｙ Ｏｆ Ｃｈｉｃａｇｏ 感染防御ブドウ球菌抗原が関与する方法および組成物
US8945588B2 (en) 2011-05-06 2015-02-03 The University Of Chicago Methods and compositions involving protective staphylococcal antigens, such as EBH polypeptides
EP2844275B1 (de) 2012-04-26 2020-05-13 University of Chicago Staphylokokken-coagulase-antigene und verfahren zu deren verwendung
GB201310008D0 (en) 2013-06-05 2013-07-17 Glaxosmithkline Biolog Sa Immunogenic composition for use in therapy
WO2016044839A2 (en) 2014-09-19 2016-03-24 The Board Of Regents Of The University Of Texas System Compositions and methods for treating viral infections through stimulated innate immunity in combination with antiviral compounds
BE1023004A1 (fr) 2014-12-10 2016-10-31 Glaxosmithkline Biologicals Sa Procede de traitement
US11053532B2 (en) 2017-04-19 2021-07-06 CAP Diagnostics, LLC Methods for treating polymicrobial infections
US11896653B2 (en) 2017-09-13 2024-02-13 Unm Rainforest Innovations Silicified cell replicas, methods of making, and methods of using

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3345864A1 (de) 1983-12-19 1985-06-27 Egbert Frh. von 8000 München Malsen-Ponickau Impfstoff und verfahren zu seiner herstellung
NZ216119A (en) 1985-05-13 1989-01-06 Commw Scient Ind Res Org Vaccine produced using antigens of a pseudocapsule producing strain of s.aureus
US5571511A (en) * 1990-10-22 1996-11-05 The U.S. Government Broadly reactive opsonic antibodies that react with common staphylococcal antigens
US5770208A (en) 1996-09-11 1998-06-23 Nabi Staphylococcus aureus B-linked hexosamine antigen
US6936258B1 (en) 1999-03-19 2005-08-30 Nabi Biopharmaceuticals Staphylococcus antigen and vaccine

Also Published As

Publication number Publication date
DE60030274T2 (de) 2008-01-10
EP1178824A2 (de) 2002-02-13
US6294177B1 (en) 2001-09-25
AU777218B2 (en) 2004-10-07
ES2270835T3 (es) 2007-04-16
PT1178824E (pt) 2007-01-31
WO2000067785A2 (en) 2000-11-16
BR0010478A (pt) 2002-05-21
WO2000067785A3 (en) 2001-02-08
CY1105744T1 (el) 2010-12-22
DK1178824T3 (da) 2006-10-09
AU4995000A (en) 2000-11-21
US6537559B2 (en) 2003-03-25
NZ515394A (en) 2004-11-26
ATE337015T1 (de) 2006-09-15
CA2372633C (en) 2010-03-30
MXPA01011507A (es) 2002-11-07
US20020031528A1 (en) 2002-03-14
EP1178824B1 (de) 2006-08-23
CA2372633A1 (en) 2000-11-16
JP2002544169A (ja) 2002-12-24

Similar Documents

Publication Publication Date Title
ATE337015T1 (de) Aus ganzen zellen bestehender impfstoff, der staphylococcus aureus antigen enthält
DK0925073T3 (da) Staphylococcus aureus antigen
DE60026691D1 (de) Staphylococcus-antigene und impstoff
BRPI9912227A (pt) método para diagnóstico precoce in vitro de carcinomas e de seus estágios iniciais e kit para realização do método.
DK1053256T3 (da) Antistoffer mod Dødsreceptor 4 (DR4) og anvendelser deraf
CA2333875A1 (en) Redox reversible bipyridyl osmium complex conjugates
DE3783073D1 (de) Modifiziertes, durch mikroorganismen hergestelltes zellulose-gel und sein komplex mit tierischen zellen.
DE60039448D1 (de) Gegen das prostata-stammzellantigen (psca) gerichtete antikörper und deren verwendung
PT799058E (pt) Melhoramentos na funcao endometrica ou com ela relacionados
AU6303490A (en) Novel hydrophilic derivatives, their application to diagnosis and to therapeutics, diagnostic or therapeutic kits and immunological reagents
DK1151087T3 (da) Assay med mindsket baggrund
DE59010347D1 (de) Substituierte N-(Chinolin-2-yl-methoxy)benzylsulfonylharnstoffe
ATE44621T1 (de) Proteinkonjugate von penicillosaeure, ihre herstellung und verwendung.
IT1229991B (it) Miglioramenti nella,o relativi alla produzione di semi ibridi
NO20006051D0 (no) Fremgangsmåte for fremstilling av dyrkning av celleaggregater referert til som primmorfer fra dissosierte celler fra svamper, koraller og andre invertebrater, samt anvendelse av disse
ATE343401T1 (de) Radiokonjugation von internalizierungsantikörpern
Litt et al. Preservation of haemocyanin
Pratt Detection of polythionate in cultures of thiobacilli by means of the Folin–Ciocalteu reagent
AR014969A1 (es) Formulacion que contienen por lo menos una proteina tardia (proteina l) de uno o mas papilomavirus y/o por lo menos una proteina temprana (proteina e) deuno o mas papilomavirus, procedimiento para la preparacion de la formulacion mencionada asi como su utilizacion para la manufactura de un medicamen
FR2279747A1 (fr) Procede de preparation d'heterocycles 1,3-diazotes a cinq ou six chainons fusionnes en 1,2, ainsi que leur utilisation comme agents de protection contre la corrosion
ATE416611T1 (de) Quelle für zellkerne zum kern-transfer
Tsai Factors Impeding Rural People's Participation in Rural Development Planning in Taiwan
JPS57131723A (en) Enzymatic activity inhibiting agent
RU98123923A (ru) Штамм гибридных культивируемых клеток животных mus musculus l., используемый для получения моноклональных антител к chlamydia
DE3850325D1 (de) Monoklonalantikörper MZ gegen Ganglioside GD, MZ produzierende Zellen und MZ enthaltendes Agens.

Legal Events

Date Code Title Description
8332 No legal effect for de
8370 Indication related to discontinuation of the patent is to be deleted
8364 No opposition during term of opposition